Medicines for Europe members publish disclosure of Transfers of Value to the healthcare community

22 June 2018

Medicines for Europe is committed to bringing accessible, high quality […]

Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest

14 June 2018

The joint 24th Medicines for Europe and 21st IGBA Annual […]

SPC manufacturing waiver, Competition policy, Brexit, pharma incentives European Patent Office take centre stage at 14^th Legal Affairs Conference

25 April 2018

Key authorities, lawyers and industry leaders discussed today in London […]

Joint Declaration on Pharmaceuticals in the Environment

10 April 2018

We, the signatories of this declaration, recognise and understand the […]

Statement in response to the EU Council ratifying the Brexit transition deal

23 March 2018

Today’s agreement on a transition period is welcome news for […]

European health community issues key questions Article 50 negotiations must answer for patients and public health

8 March 2018

The European Health Community has warned that time is running […]

Supply chain commitment to tackling problem of medicine shortages

2 March 2018

IGBA congratulates the Australian government for maintaining their biologics naming convention and for strengthening pharmacovigilance

29 January 2018

2018 – A year of unprecedented challenges and opportunities for pharmaceutical regulatory systems

25 January 2018

This week in London, Medicines for Europe gathers regulators and […]

Vigilance saves lives! More focus needed on sustainability and patient engagement

24 January 2018

National authorities, regulators, industry leaders and key stakeholders gathered in […]